“From 1 January the medicine Xalkori® (crizotinib) will made available through the Pharmaceutical Benefits Scheme (PBS) for lung cancer patients with a c-ROS proto-oncogene 1 (ROS1) gene rearrangement. The drug may stop or slow the growth of Stage IIIB (locally advanced) or Stage IV (metastatic) non-small cell lung cancer. Without the PBS subsidy the drug … Continue reading Crizotinib approved for ROS1 in Australia
Read about Corinne’s journey living with ROS1 positive lung cancer. “I didn’t realize it, but I was rapidly declining, dying, in late January 2016.” ” Were you WOWed reading that, knowing that I’m still here and functioning well three years after that? I was pretty darned impressed with what medical research has made possible.”
Marisa was diagnosed with Stage IV Adenocarcinoma in October 2015 at the age of 30. Read her inspiring post about completing grad school while living with lung cancer. “On January 12th, I submitted my final assessment for grad school. Four-hundred-and-sixty-eight days following my first footsteps into the Poli Sci department at UCL. I will never … Continue reading Learning and the Passage of Time – A blog post by Marisa
“Pfizer Inc. (NYSE:PFE) today announced that the U.S. Food and Drug Administration (FDA) has approved LORBRENA® [lor-BREN-ah] (lorlatinib), a third-generation anaplastic lymphoma kinase (ALK) tyrosine kinase inhibitor (TKI) for patients with ALK-positive metastatic non-small cell lung cancer (NSCLC) whose disease has progressed on crizotinib and at least one other ALK inhibitor for metastatic disease; or … Continue reading U.S. FDA Approves LORBRENA® (lorlatinib) for Previously-Treated ALK-Positive Metastatic NSCLC
“No testing methodology demonstrated 100% sensitivity in the detection of ROS1 rearrangements or fusions among patients with non-small cell lung cancer, according to study results.” “The main point is just to be aware of the deficiencies in these assays and not to always trust a negative result from a single test,” Kurtis D. Davies, PhD, … Continue reading Detection of ROS1 rearrangement in lung cancer remains “complex”
Loss of G2032R Resistance Mutation Upon Chemotherapy Treatment Enables Successful Crizotinib Rechallenge in a Patient With ROS1-Rearranged NSCLC. This case is a proof of concept that re-challenging with crizotinib after intervening chemotherapy is feasible in ROS1-rearranged NSCLC with acquired resistance. Read full article here.